Recent Updates — ENTXW

Entera Bio Ltd. announced on August 18, 2026, the appointment of Dr. Riccardo Paolo Camisasca as its new Chief Medical Officer, effective immediately. Dr. Camisasca brings over 30 years of experience in clinical development and R&D leadership, most recently serving as Global Head of Research & Development at Sumitomo Pharma Switzerland. His appointment is intended to strengthen the company's clinical execution team ahead of the planned Phase 3 initiation for EB613, an oral anabolic treatment for osteoporosis. Entera Bio Ltd. operates in the biotechnology industry and develops oral peptide therapies.

Entera Bio Ltd. announced its financial results for the three months ended June 30, 2026, reporting a net loss of $7.3 million ($0.14 per share) compared to $2.7 million in the prior year period. The company also disclosed key business updates, including positive FDA feedback on a planned 12-month Phase 3 registrational study for EB613, an oral anabolic tablet for osteoporosis, with initiation expected in late 2026 and topline data anticipated in the second half of 2028. Additionally, Entera reported that it oversubscribed a $275 million private placement led by BVF Partners in July 2026, which will fund EB613 through NDA submission and extend its cash runway into 2030. The company is developing oral peptide therapies for unmet medical needs.

At its 2026 Annual Meeting of Shareholders on July 14, 2026, Entera Bio Ltd. shareholders approved an amendment to the 2018 Equity Incentive Plan to increase the number of ordinary shares issuable by 2,500,000 shares. Additionally, shareholders approved an amendment to the Articles of Association to increase the authorized Ordinary Shares from 140,010,000 to 350,000,000. Entera Bio Ltd. is a biotechnology company focused on developing oral peptide therapeutics.